Release Date: May 10, 2024
Expiration Date: May 10, 2025

Expected time to complete this activity as designed:  60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

VTE is a challenging and complex disease to treat in patients with standard risk factors. In patients with multiple comorbidities, unique physiological challenges or who have transient risk factors such as pregnancy or COVID, the complexity of safely and effectively treating VTE in a non-specialist setting increases significantly. Through discussions of specific case studies, this accredited activity will feature a panel of experts in hematology/VTE and pharmacy providing clear and specific recommendations for best practices in these challenging and unique patients – as well as guidance on clinical strategies that are less effective or should be avoided in elderly patients, patients with renal disease, obese patients, women, patients with COVID and patients in whom anticoagulation therapy seems to have failed.

Target Audience

The target audience is the multidisciplinary team of physicians, nurses and other allied healthcare professionals specializing in primary care, general practice, family practice and internal medicine who provide healthcare for patients with VTE.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

• Outline considerations for treating VTE in special populations, including elderly patients, obese patients, and post-bariatric surgery patients
• Summarize strategies for anticoagulation in woman with heavy menstrual bleeding and women with childbearing potential
• Evaluate the risk of developing COVID-related thrombosis in patients following infection with, or vaccination for, COVID
• Identify strategies for determining if a patient with a recurrent clot has experienced anticoagulation failure

Agenda

Practical Strategies for Long-Term VTE Management in Unique Patient Populations

• Elderly patients with VTE
• Patients with renal dysfunction and VTE
• Obese patients with VTE: bariatric surgery and weight loss medications
• Women with VTE: heavy menstrual bleeding, contraception, and pregnancy
• COVID and VTE
• Anticoagulation failure and recurrent clots

Instructions for Participation and Credit

This activity is eligible for credit through May 10, 2025. After this date, this activity will expire and no further credit will be awarded.

1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CME, CE, and CNE may be printed immediately after successfully completing the post-test and activity evaluation.

Faculty Biographies

Jori May, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
The University of Alabama at Birmingham School of Medicine
Birmingham, Alabama

Dr. Jori May received her medical degree from Washington University School of Medicine in St. Louis, Missouri and completed an Internal Medicine residency, chief residency, and Hematology/Oncology fellowship at The University of Alabama at Birmingham (UAB) School of Medicine. She is currently an Assistant Professor of Medicine in the Division of Hematology/Oncology at UAB. She specializes in caring for patients with thrombosis and coagulation disorders and is the Physician Advisor for Hemostatic and Antithrombotic Stewardship for UAB Medicine. 

Dr. May is a board member of the Anticoagulation Forum and an active member of the American Society of Hematology, currently serving on the Committee on Quality. She is also an active medical educator, including roles within UAB’s medical school, internal medicine residency, and fellowship programs.

Stephan Moll, MD
Professor
Department of Medicine
Division of Hematology
University of North Carolina
Chapel Hill, North Carolina

Dr. Stephan Moll received his medical degree from Freiburg University, Germany, and performed a pathology residency at the Institute of Pathology, University of Aachen, Germany. He completed an internship/residency in internal medicine and a hematology-oncology fellowship at Duke University Medical Center, North Carolina, and a one-year clinical coagulation fellowship at the University of North Carolina (UNC), Chapel Hill. Dr. Moll has been a faculty member at the University of North Carolina in the Department of Medicine and the Division of Hematology-Oncology since 1999, now at the rank of full professor.

His clinical interest is coagulation and classical hematology, with a particular focus on thrombosis and anticoagulation. Dr Moll’s research interests include clinical trials on new anticoagulants and better use of established anticoagulants. He takes a special interest in clinical-medical education of patients, the public, and healthcare professionals, and is a cofounder of the UNC Blood Clot Education Program Clot Connect. His three main professional goals for the next 5-10 years are 1) enhance the Clot Connect information program, 2) continue to build an “Athletes and Blood Clot Program,” 3) support trainees in their career development in the field of coagulation/hematology.

William Braun, PharmD
Pharmacy Clinical Coordinator
BayCare Health System
Clearwater, Florida
PGY1 Pharmacy Residency Program Director
Assistant Pharmacy Professor
University of Florida

Dr. William Braun is a Pharmacy Clinical Coordinator for the BayCare Health System at St. Anthony’s Hospital, part of the BayCare Health System. He is also a Clinical Assistant Professor for the University of Florida and the BayCare St. Anthony’s Hospital Pharmacy Residency Program Director.

Dr. Braun has been involved in numerous research investigations including the investigation of COVID-19 and VTE prophylaxis and participated in the Hep-COVID trial. He is actively involved in research investigating chemical VTE prophylaxis. Dr. Braun has also played an integral part in the evaluation and implementation of thrombolytics and stroke comparing tenecteplase versus alteplase in large vessel occlusions.

Accreditation

	CME CREDIT MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
	NURSING CREDIT MediCom Worldwide, Inc.is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 24-022-178

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.

Faculty Disclosures

Dr. Jori May and Dr. William Braun have no relevant financial relationships to disclose.

Dr. Stephan Moll has relevant financial relationships related to consulting from Diagnostica Stago, Inc.

All of the relevant financial relationships listed for these individuals have been mitigated.

Unapproved Product Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.

Planning Committee

Joan Meyer, RN, MHA, Executive Director; Sheri Sturgis, Strategy and Education Manager; Lillian McVey, Content Director; and Jennifer Murphy, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer

Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected]

Provided by MediCom Worldwide, Inc.

This activity is supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance.

©2024 MediCom Worldwide, Inc., 4607 Library Rd., Ste. 220 #2001 · Bethel Park, PA 15102, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.